-
-
-
-
-
-
-
Cantor Fitzgerald Starts Tenax Therapeutics (TENX) at Overweight
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
Tenax Therapeutics (TENX) Misses Q4 EPS by 18c
-
-
-
-
-
-
-
Leerink Partners Starts Tenax Therapeutics (TENX) at Outperform
-
-
-
426,513 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

